OFA
SRNE

Oaktree Fund Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Oaktree Fund Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66,000
Closed -$23.8K – 49
2023
Q1 		$23.8K Hold
66,000
– – 0.02% 38
2022
Q4 		$58.5K Hold
66,000
– – 0.09% 16
2022
Q3 		$103K Hold
66,000
– – 0.16% 15
2022
Q2 		$132K Buy
66,000
+16,000
+32% +$27.7K 0.23% 14
2022
Q1 		$116K Hold
50,000
– – 0.19% 14
2021
Q4 		$232K Sell
50,000
-16,000
-24% -$99.3K 0.48% 13
2021
Q3 		$503K Hold
66,000
– – 48.93% 1
2021
Q2 		$640K Buy
+66,000
New +$526K 60.89% 1

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Oaktree Fund Advisors's SRNE Position: Q2 2023 in Review

Oaktree Fund Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 66,000 shares — an estimated $23.8K sold.

Oaktree Fund Advisors first reported a position in SRNE in Q2 2021 and held it in 8 quarters. The position peaked at $640K in Q2 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • Oaktree Fund Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Oaktree Fund Advisors sold 66,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $23.8K.
  • Oaktree Fund Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2021 and held it in 8 quarters.
  • Oaktree Fund Advisors's Sorrento Therapeutics, Inc. position peaked at $640K in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Oaktree Fund Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.